Skip to content
10-Q

Quarterly Report

ADIAL PHARMACEUTICALS, INC. ADIL

0001213900-26-053907

← back to feed
Filed
May 8, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 6, 2026 2.14M sh
Shares Diluted Q1 2026 · Mar 31, 2026 1.37M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 261.59K sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$1.61M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$1.59M
Stockholders Equity Q1 2026 · Mar 31, 2026 $3.72M
Stockholders Equity Q1 2026 · Dec 31, 2025 $5.28M
Stockholders Equity Q1 2026 · Mar 31, 2025 $2.13M
Stockholders Equity Q1 2026 · Dec 31, 2024 $4.07M
Current Liabilities Q1 2026 · Mar 31, 2026 $1.51M
Current Liabilities Q1 2026 · Dec 31, 2025 $1.4M
Total Liabilities Q1 2026 · Mar 31, 2026 $1.51M
Total Liabilities Q1 2026 · Dec 31, 2025 $1.4M
Current Assets Q1 2026 · Mar 31, 2026 $4.8M
Current Assets Q1 2026 · Dec 31, 2025 $6.18M
Total Assets Q1 2026 · Mar 31, 2026 $5.23M
Total Assets Q1 2026 · Dec 31, 2025 $6.67M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.48
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$8.52
Eps Basic Q1 2026 · Mar 31, 2026 −$1.48
Eps Basic restated Q1 2026 · Mar 31, 2025 −$8.52
Sga Expense Q1 2026 · Mar 31, 2026 $1.57M
Sga Expense Q1 2026 · Mar 31, 2025 $1.52M
Rd Expense Q1 2026 · Mar 31, 2026 $432.53K
Rd Expense Q1 2026 · Mar 31, 2025 $746.89K
Net Income Q1 2026 · Mar 31, 2026 −$2.02M
Net Income Q1 2026 · Mar 31, 2025 −$2.23M
Operating Income Q1 2026 · Mar 31, 2026 −$2M
Operating Income Q1 2026 · Mar 31, 2025 −$2.27M